Biomerica (NASDAQ:BMRA) is up 23% premarket on the heels of submitting
an Emergency Use Authorization (EUA) application to the FDA for an
ELISA lab-based serology blood test for the detection of antibodies that
identify if a person is infected with COVID-19.
This is the third COVID-19 antibody test introduced by the Company. The other two, which are finger-prick rapid tests.
BMRA also intends to obtain a CE mark to market and sell this ELISA laboratory test outside the US.
https://seekingalpha.com/news/3583377-biomerica-files-for-emergency-use-of-covidminus-19-blood-test
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.